Targeting the Jak/Signal Transducer and Activator of Transcription 3 Pathway with Ruxolitinib in a Mouse Model of Recessive Dystrophic Epidermolysis Bullosa-Squamous Cell Carcinoma

J Invest Dermatol. 2021 Apr;141(4):942-946. doi: 10.1016/j.jid.2020.08.022. Epub 2020 Oct 16.

Affiliations

¹ Department of Dermatology, Columbia University, New York, New York, USA; St John's Institute of Dermatology, King's College London (Guy's campus), London, United Kingdom.
² Department of Dermatology, Columbia University, New York, New York, USA.
³ Department of Dermatology, Columbia University, New York, New York, USA; Department of Genetics and Development, Columbia University, New York, New York, USA. Electronic address: amc65@columbia.edu.

PMID: 33069729
DOI: 10.1016/j.jid.2020.08.022

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Animals
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / genetics
Carcinoma, Squamous Cell / pathology
Cell Line, Tumor
Collagen Type VII / genetics
Epidermolysis Bullosa Dystrophica / complications
Epidermolysis Bullosa Dystrophica / drug therapy*
Epidermolysis Bullosa Dystrophica / genetics
Fibroblasts
Humans
Janus Kinases / antagonists & inhibitors*
Janus Kinases / metabolism
Mice
Mutation
Nitriles
Pyrazoles / administration & dosage*
Pyrazoles / pharmacology
Pyrimidines
STAT3 Transcription Factor / metabolism
Signal Transduction / drug effects
Skin Neoplasms / drug therapy*
Skin Neoplasms / genetics
Skin Neoplasms / pathology
Xenograft Model Antitumor Assays

Substances

COL7A1 protein, human
Collagen Type VII
Nitriles
Pyrazoles
Pyrimidines
STAT3 Transcription Factor
STAT3 protein, human
ruxolitinib
Janus Kinases